Name: 글로벌 시장 동향
SKU: PH1613
Availability: InStock

보고서 요약(국문)

개요
글로벌 면역항암 검사 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
면역항암은 암의 면역 체계에 초점을 맞추며, 국소암 및 진행성 전이암에서 우수한 치료 효과를 보입니다. 현재 250건 이상의 임상 시험이 진행 중이며, 새로운 면역생물학적 치료법 개발에 힘쓰고 있습니다. 또한, 특정 암 유형 및 전이 진단에 도움이 되는 다양한 검사법이 개발 단계에 있습니다.
이러한 검사법은 암세포 증식 및 전이를 지속적이고 실시간으로 분석하는 데 유용합니다. 세포 사멸 검사, 세포 증식 검사, 기타 면역 세포 검출 검사 등 다양한 검사를 통해 개인의 특정 암 유형을 진단할 수 있습니다.

범위

시장 동향: 동인 및 제약 요인
면역항암 분야의 발전 증가
면역항암 검사의 발전은 암 진단 및 치료 가능성을 높이기 위한 노력의 일환입니다. 다양한 연구비 지원을 통해 출시되는 신제품들은 암 연구를 가속화하고 있으며, 이는 다른 유형의 암으로 고통받는 사람들의 치료 개선에도 도움이 됩니다. 특히 흑색종, 대장암 등 흔한 암에 대한 연구가 활발히 진행되고 있습니다. 예를 들어, 2022년 5월 Labcorp는 흑색종 종양에서 면역조직화학(IHC)을 이용하여 유전자 발현 수준을 측정하는 새로운 검사를 출시했습니다.

2022년 11월 Akoya Biosciences는 고처리량 공간 바이오마커 발굴을 위한 PhenoCode Signature Panels을 출시했습니다. 이는 면역항암 분야에 적용될 수 있는 예측 바이오마커의 개발 및 검증을 가속화합니다.

2022년 3월, 루나포어(Lunaphore)는 면역항암 포트폴리오 구축에 도움이 되는 공간 생물학 기술을 도입하고자 하는 연구실에 특별한 기회를 제공하기 위해 2023년 SPYRE 면역항암 연구비 지원 프로그램을 발표했습니다.
2022년 5월, 베라사이트(Veracyte, Inc.)는 전이성 직장암(mCRC) 환자를 식별하는 자사의 이뮤노스코어(Immunoscore) 면역 체크포인트(IC) 검사에 대한 새로운 데이터를 발표했습니다.
또한, 암 치료에 대한 연구 관심 증가, 다양한 진단 절차에 대한 인식 제고, 그리고 기술 발전은 향후 시장 성장을 견인할 몇 가지 요인입니다.
전문성 부족
면역항암학은 끊임없이 발전하고 있기 때문에, 면역항암학에 대한 기초 지식이 부족하여 검사법의 활용 및 분석에 대한 지식 부족 현상이 시간이 지남에 따라 심화될 것입니다. 데이터 분석에는 면역학과 종양학 분야 모두에 대한 높은 전문성이 요구됩니다. 그렇지 않으면 위양성 또는 위음성 결과가 나오거나, 결과가 제대로 검출되지 않을 가능성이 있습니다. 확립된 절차가 없어 표준 면역 검사 절차보다 오류율이 높습니다.
또한, 검사 오류, 숙련된 전문가 부족 등은 향후 시장 성장을 저해하는 몇 가지 요인입니다.
이 보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
글로벌 면역항암 검사는 제품 및 서비스, 검사 유형, 기술, 적응증, 최종 사용자 및 지역별로 세분화됩니다.
면역 검사 부문은 시장 점유율의 약 48.6%를 차지했습니다.
면역 검사 부문은 시장에서 가장 큰 비중을 차지할 것으로 예상됩니다. 면역항암은 특이성과 지속성으로 인해 암 치료에 있어 주목할 만한 접근법으로 자리 잡았습니다. 면역 세포 사멸 검사, 세포 증식 검사, 차세대 염기서열 분석 검사와 같은 검사는 암이 전이되기 전에 질병을 보다 정확하게 발견하고 치료할 수 있도록 개발되었습니다. 따라서 새로운 면역항암 검사의 출시는 암 전이 탐지의 특이성을 높이는 데 도움이 됩니다.

2023년 4월, 애질런트 테크놀로지스(Agilent Technologies Inc.)는 정밀 면역항암요법 발전을 위한 차세대 염기서열 분석(NGS) 검사인 애질런트 슈어셀렉트 암 CGP 검사(Agilent SureSelect Cancer CGP Assay)를 출시했습니다. 이 검사는 다양한 종양 유형을 분석하는 데 도움을 줍니다.
2022년 1월, 온코사이트(Oncocyte)는 써모 피셔 사이언티픽(Thermo Fisher Scientific)과 온코마인 종합 검사 플러스(Oncomine Comprehensive Assay Plus)의 임상 검증 계약을 체결했다고 발표했습니다. 이 계약은 면역항암요법에 대한 반응을 예측할 수 있는 디터마IO(DetermaIO) 검사를 개발하는 것을 목표로 합니다.
지역별 분석
북미는 2022년 시장 점유율의 약 40.5%를 차지했습니다.
북미는 미국 내 암 발병률과 암 치료 지출이 높은 점을 고려할 때 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 써모 피셔 사이언티픽, 루나포어(Lunafore) 등 주요 업체들은 새로운 면역항암 검사 출시를 위해 지속적으로 노력하고 있으며, 일부는 아직 테스트 단계에 있지만 곧 출시될 예정입니다.

JAMA Health Forum 2022에 따르면, 미국의 암 치료 지출은 비슷한 추세를 보이며 2020년에 2,000억 달러를 넘어섰습니다. 미국의 국가 암 치료 지출은 다른 22개국에 비해 높았습니다. 이러한 지출은 암 치료 결과 개선을 위해 증가할 것으로 예상됩니다.
미국 암 학회지에 따르면, 2022년 미국에서만 약 190만 건의 새로운 암 환자가 진단되고 609,360명이 암으로 사망할 것으로 추정됩니다.
COVID-19 영향 분석
COVID-19는 면역항암 검사 시장에 영향을 미쳤습니다. 전 세계적인 봉쇄 조치 시행으로 인해 대부분의 전문 진단 센터는 팬데믹 중반기에 COVID-19 확진자 급증으로 인해 면역항암 검사 서비스를 중단하거나 폐쇄했습니다. 사람들은 감염에 대한 두려움 때문에 검사를 받지 않았습니다. 대부분의 검사 절차는 중단되거나 나중 단계로 연기되었습니다. 코로나19 확진자 증가로 인해 질병 진단을 위한 코로나19 진단 키트 제조에 초점이 맞춰졌습니다.
경쟁 환경
면역항암제 검사 시장의 주요 글로벌 업체로는 Merck KGaA, Thermo Fisher Scientific Inc., Crown Bioscience, Lunaphore Technologies SA., Eve Technologies., Vivia Biotech S.L, Illumina, Inc., Bio-Rad Laboratories, Inc., Charles River Laboratories, PerkinElmer Inc. 등이 있습니다.
주요 개발 사항
2023년 4월, 세계적인 액체 생검 기업인 ANGLE plc는 임상 단계의 면역항암제 기업인 Crescendo Biologics Limited와 계약을 체결했습니다. Crescendo는 ANGLE이 최근 개발한 Flex Assay를 PSMA 양성 고형암 환자 치료에 사용할 계획입니다.

2023년 9월, Cytek Biosciences, Inc.는 2023년 10월 5일에 개최될 예정인 글로벌 로드쇼 'Cytek Reveal'을 발표했습니다. 이 회사의 특허 기술인 Full Spectrum Profiling(FSP) 기술은 과학자들이 면역항암제 검사 솔루션을 개발할 수 있도록 지원합니다.
2023년 5월, Memorial Sloan Kettering Cancer Center(MSK)는 Marie-Josée Kravis Center for Cancer Immunobiology(CCI)에 4천만 달러를 투자한다고 발표했습니다. 이 면역항암제 연구 허브 설립은 면역항암제 발견, 세포 공학, 면역 진단 검사 등의 발전을 촉진하는 데 도움이 될 것입니다.
보고서 구매 이유:

• 제품 및 서비스, 검사 유형, 기술, 적응증, 최종 사용자 및 지역별 글로벌 면역항암제 검사 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해
• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별하기 위해
• 모든 세그먼트를 포함한 면역항암제 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공.
글로벌 면역항암제 시장 보고서는 약 77개의 표, 84개의 그림, 195페이지 분량으로 구성됩니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Immuno Oncology Assays Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
Immuno-oncology focuses on the immune system in cancer, which shows better results in localized and advanced metastatic cancers. Over 250 clinical trials are currently in progress to develop novel immunobiological treatments, and several assays are in the pipeline that help in diagnosing specific cancer types and their metastasis.
These assays are helpful in continuous and real-time cancer cell proliferation and metastasis analysis. Multiple assays, such as cell killing assays, cell proliferation assays, and other immune cell detection assays, help detect specific cancer types in individuals.
Scope

Market Dynamics: Drivers & Restraints
Increasing developments in immuno oncology sector
Developments in immuno oncology testing in an attempt to increase the prospects of cancer diagnosis and treatment. Launch of new products coming up with different grants speed up cancer research, which is helpful for better cancer treatment for individuals suffering from other types of cancers. The main focus is on melanoma, colorectal cancers, etc., as these are observed in most individuals. For instance, in May 2022, Labcorp launched a new test to measure gene expression levels by immunohistochemistry (IHC) in tumors observed in melanoma.
In November 2022, Akoya Biosciences, Inc. launched PhenoCode Signature Panels for high-throughput spatial biomarker discovery. This accelerates the development and validation of predictive biomarkers for immuno-oncology applications.
In March 2022, Lunaphore declared a 2023 SPYRE Immuno-Oncology Grant Program to provide a unique opportunity for the laboratories looking to adopt spatial biology technology that helps establish an immuno-oncology portfolio.
In May 2022, Veracyte, Inc. declared new data showing the company’s Immunoscore Immune Checkpoint (IC) assay, which identifies patients with metastatic colorectal cancer (mCRC).
Furthermore, increased research focus on cancer therapy, rising awareness about different diagnosis procedures, and advancements are a few factors that drive the market in the forthcoming period.
Lack of expertise
Immuno-oncology is constantly evolving, and hence, the deficit in the knowledge of handling and analyzing the assays will increase over time as there is no basic knowledge of immuno-oncology. The data analysis requires strong expertise in both the immunology and oncology sectors. Otherwise, there is a possibility of false outcomes that show false positive or false negative results, or the results cannot be detected. There are no established procedures, so the error rate is higher than in standard immuno-testing procedures.
Furthermore, errors in assays, lack of skilled professionals are few factors that hamper the market in the forthcoming period.
For more details on this report – Request for Sample
Segment Analysis
The global immuno-oncology assays are segmented based on products and services, assay type, technology, indication, end user and region.
The Immunoassay segment accounted for approximately 48.6% of the market share
The immunoassay segment is expected to hold the largest share of the market. Immuno-oncology has become an exciting approach to cancer treatment due to its specificity and durability. The assays like immuno-cell killing assays, cell proliferation assays, and next-generation sequencing assays are developed as their approach is exact and accurate in finding and treating the disease more precisely before the cancer undergoes metastasis. Hence, new immuno-oncology assay launches help increase the specificity for detecting cancer metastasis.
In April 2023, Agilent Technologies Inc. launched Agilent SureSelect Cancer CGP Assay, an NGS assay for advancing precision immuno-oncology. It helps in profiling a broad range of tumor types.
In January 2022, Oncocyte declared that it had agreed with Thermo Fisher Scientific to validate Oncomine Comprehensive Assay Plus clinically. This agreement aims to develop the DetermaIO test that may predict responses to immuno-oncology therapies.
Geographical Analysis
North America accounted for approximately 40.5% of the market share in 2022
North America is expected to hold the largest market share owing to the prevalence of cancer cases in the US and expenditure for cancer care. Significant players like Thermo Fisher Scientific, Lunafore, etc., are continuously working on launching new immune-oncology assays shortly, as a few of them are still in the testing stage, which will be released soon.
According to the JAMA Health Forum, 2022, US cancer care spending has followed a similar pattern, surpassing $200 billion in 2020. National cancer care expenditures were high in the US compared to the other 22 countries. This spending is expected to increase to improve cancer care outcomes.
According to the American Cancer Society journal, In 2022, an estimated 1.9 million new cancer cases will be diagnosed and 609,360 cancer deaths in the United States alone.
COVID-19 Impact Analysis
COVID-19 has shown an impact on the immuno-oncology assay market. Due to the implementation of lockdowns worldwide, most specialty diagnostic centers have shut down or stopped the services that provide immuno-oncology testing due to the surge in COVID-19 in the mid-pandemic phase. People restricted themselves from getting tested because they feared contracting the disease. Most of the testing procedures were halted and postponed to later stages. Due to the rise in COVID-19 cases, there was a shift in the focus of manufacturing COVID-19 testing kits for disease diagnosis.
Competitive Landscape
The major global players in the immuno oncology assays market include Merck KGaA, Thermo Fisher Scientific Inc., Crown Bioscience, Lunaphore Technologies SA., Eve Technologies., Vivia Biotech S.L, Illumina, Inc., Bio-Rad Laboratories, Inc, Charles River Laboratories, PerkinElmer Inc. among others.
Key Developments
In April 2023, ANGLE plc, a world-leading liquid biopsy company signed a contract with Crescendo Biologics Limited, a clinical-stage immuno-oncology company. Crescendo is planning to use a recently launched flex assay developed by ANGLE for the treatment of patients with PSMA positive solid tumors.
In September 2023, Cytek Biosciences, Inc. launched a global road show called Cytek Reveal that is to be held on October 5th, 2023. The company's patented Full Spectrum Profiling (FSP) technology empowers scientists to work on immuno-oncology testing solutions.
In May 2023, Memorial Sloan Kettering Cancer Center (MSK) declared $40M for Marie-Josée Kravis Center for Cancer Immunobiology (CCI). This creation of an immuno-oncology hub helps in progressing immuno-oncology discovery, cell engineering, immuno-diagnostic assays, etc.
Why Purchase the Report?
• To visualize the global immuno oncology assays market segmentation based on products and services, assay type, technology, indication, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of immuno oncology assays market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global immuno oncology assays market report would provide approximately 77 tables, 84 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Products and Services
3.2. Snippet by Assay Type
3.3. Snippet by Technology
3.4. Snippet by Indication
3.5. Snippet by End User
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Driver
4.1.1.1. Increasing developments in immune-oncology sector
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. Lack of Expertise
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Products and Services
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
7.1.2. Market Attractiveness Index, By Products and Services
7.2. Instruments*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Consumables
7.4. Software and Services
8. By Assay Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
8.1.2. Market Attractiveness Index, By Assay Type
8.2. Cell proliferation assays*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cell migration and invasion assays
8.4. Phagocytosis assays
8.5. Immune cell killing assays
8.6. Others
9. By Technology
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.1.2. Market Attractiveness Index, By Technology
9.2. PCR*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. NGS
9.4. ISH
9.5. Immunoassay
9.6. Flow cytometry
9.7. Others
10. By Indication
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.1.2. Market Attractiveness Index, By Indication
10.2. Colorectal cancer*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Breast Cancer
10.4. Lung Cancer
10.5. Melanoma
10.6. Others
11. By End User
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.1.2. Market Attractiveness Index, By End User
11.2. Academic Institutes*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Research Organizations
11.4. Diagnostics centers
11.5. Others
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.8.1. Germany
12.3.8.2. UK
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. Company Profiles
14.1. Merck KGaA
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Thermo Fisher Scientific Inc.
14.3. Crown Bioscience
14.4. Lunaphore Technologies SA.
14.5. Eve Technologies.
14.6. Vivia Biotech S.L
14.7. Illumina, Inc.
14.8. Bio-Rad Laboratories, Inc
14.9. Charles River Laboratories
14.10. PerkinElmer Inc.
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

언급된 주요 기업들

Merck KGaA, 4. Key Developments, Thermo Fisher Scientific Inc., Crown Bioscience, Lunaphore Technologies SA., Eve Technologies., Vivia Biotech S.L, Illumina, Inc., Bio-Rad Laboratories, Inc, Charles River Laboratories, PerkinElmer Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Immuno-Oncology Assays Market Value, By Product Type, 2025, 2029 & 2033 (US$ Million)

Table 2 Global Immuno-Oncology Assays Market Value, By Assay Type, 2025, 2029 & 2033 (US$ Million)

Table 3 Global Immuno-Oncology Assays Market Value, By Technology, 2025, 2029 & 2033 (US$ Million)

Table 4 Global Immuno-Oncology Assays Market Value, By Indication, 2025, 2029 & 2033 (US$ Million)

Table 5 Global Immuno-Oncology Assays Market Value, By End User, 2025, 2029 & 2033 (US$ Million)

Table 6 Global Immuno-Oncology Assays Market Value, By Region, 2025, 2029 & 2033 (US$ Million)

Table 7 Global Immuno-Oncology Assays Market Value, By Product Type, 2025, 2029 & 2033 (US$ Million)

Table 8 Global Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)

Table 9 Global Immuno-Oncology Assays Market Value, By Assay Type, 2025, 2029 & 2033 (US$ Million)

Table 10 Global Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)

Table 11 Global Immuno-Oncology Assays Market Value, By Technology, 2025, 2029 & 2033 (US$ Million)

Table 12 Global Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)

Table 13 Global Immuno-Oncology Assays Market Value, By Indication, 2025, 2029 & 2033 (US$ Million)

Table 14 Global Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)

Table 15 Global Immuno-Oncology Assays Market Value, By End User, 2025, 2029 & 2033 (US$ Million)

Table 16 Global Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)

Table 17 Global Immuno-Oncology Assays Market Value, By Region, 2025, 2029 & 2033 (US$ Million)

Table 18 Global Immuno-Oncology Assays Market Value, By Region, 2022-2033 (US$ Million)

Table 19 North America Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)

Table 20 North America Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)

Table 21 North America Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)

Table 22 North America Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)

Table 23 North America Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)

Table 24 North America Immuno-Oncology Assays Market Value, By Country, 2022-2033 (US$ Million)

Table 25 South America Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)

Table 26 South America Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)

Table 27 South America Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)

Table 28 South America Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)

Table 29 South America Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)

Table 30 South America Immuno-Oncology Assays Market Value, By Country, 2022-2033 (US$ Million)

Table 31 Europe Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)

Table 32 Europe Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)

Table 33 Europe Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)

Table 34 Europe Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)

Table 35 Europe Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)

Table 36 Europe Immuno-Oncology Assays Market Value, By Country, 2022-2033 (US$ Million)

Table 37 Asia-Pacific Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)

Table 38 Asia-Pacific Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)

Table 39 Asia-Pacific Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)

Table 40 Asia-Pacific Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)

Table 41 Asia-Pacific Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)

Table 42 Asia-Pacific Immuno-Oncology Assays Market Value, By Country, 2022-2033 (US$ Million)

Table 43 Middle East and Africa Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)

Table 44 Middle East and Africa Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)

Table 45 Middle East and Africa Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)

Table 46 Middle East and Africa Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)

Table 47 Middle East and Africa Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)

Table 48 Middle East and Africa Immuno-Oncology Assays Market Value, By Country, 2022-2033 (US$ Million)

Table 49 Merck KGaA: Overview

Table 50 Merck KGaA: Product Portfolio

Table 51 Merck KGaA: Key Developments

Table 52 Thermo Fisher Scientific Inc.: Overview

Table 53 Thermo Fisher Scientific Inc.: Product Portfolio

Table 54 Thermo Fisher Scientific Inc.: Key Developments

Table 55 Lunaphore Technologies SA.: Overview

Table 56 Lunaphore Technologies SA.: Product Portfolio

Table 57 Lunaphore Technologies SA.: Key Developments

Table 58 Eve Technologies: Overview

Table 59 Eve Technologies: Product Portfolio

Table 60 Eve Technologies: Key Developments

Table 61 Vivia Biotech S.L: Overview

Table 62 Vivia Biotech S.L: Product Portfolio

Table 63 Vivia Biotech S.L: Key Developments

Table 64 Illumina, Inc.: Overview

Table 65 Illumina, Inc.: Product Portfolio

Table 66 Illumina, Inc.: Key Developments

Table 67 Charles River Laboratories: Overview

Table 68 Charles River Laboratories: Product Portfolio

Table 69 Charles River Laboratories: Key Developments

Table 70 Bio-Techne: Overview

Table 71 Bio-Techne: Product Portfolio

Table 72 Bio-Techne: Key Developments

Table 73 Creative Biolabs: Overview

Table 74 Creative Biolabs: Product Portfolio

Table 75 Creative Biolabs: Key Developments

Table 76 Miltenyi Biotec: Overview

Table 77 Miltenyi Biotec: Product Portfolio

Table 78 Miltenyi Biotec: Key Developments

Table 79 Adipogen Life Sciences: Overview

Table 80 Adipogen Life Sciences: Product Portfolio

Table 81 Adipogen Life Sciences: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 2 Global Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)

Figure 3 Global Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)

Figure 4 Global Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)

Figure 5 Global Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)

Figure 6 Global Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)

Figure 7 Global Immuno-Oncology Assays Market Share, By Region, 2024 & 2033 (%)

Figure 8 Global Immuno-Oncology Assays Market Y-o-Y Growth, By Product Type, 2023-2033 (%)

Figure 9 Instruments Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 10 Consumables Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 11 Software and Services Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 12 Global Immuno-Oncology Assays Market Y-o-Y Growth, By Assay Type, 2023-2033 (%)

Figure 13 Cell Proliferation Assays Assay Type in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 14 Cell Migration and Invasion Assays Assay Type in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 15 Phagocytosis Assays Assay Type in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 16 Immune Cell Killing Assays Assay Type in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 17 Others Assay Type in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 18 Global Immuno-Oncology Assays Market Y-o-Y Growth, By Technology, 2023-2033 (%)

Figure 19 PCR Technology in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 20 NGS Technology in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 21 Immunoassay Technology in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 22 Flow Cytometry Technology in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 23 Others Technology in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 24 Global Immuno-Oncology Assays Market Y-o-Y Growth, By Indication, 2023-2033 (%)

Figure 25 Colorectal Cancer Indication in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 26 Breast Cancer Indication in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 27 Lung Cancer Indication in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 28 Melanoma Indication in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 29 Others Indication in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 30 Global Immuno-Oncology Assays Market Y-o-Y Growth, By End User, 2023-2033 (%)

Figure 31 Academic Institutes End User in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 32 Research Organizations End User in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 33 Diagnostics Centers End User in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 34 Others End User in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 35 Global Immuno-Oncology Assays Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 36 North America Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 37 North America Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)

Figure 38 North America Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)

Figure 39 North America Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)

Figure 40 North America Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)

Figure 41 North America Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)

Figure 42 North America Immuno-Oncology Assays Market Share, By Country, 2024 & 2033 (%)

Figure 43 South America Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 44 South America Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)

Figure 45 South America Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)

Figure 46 South America Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)

Figure 47 South America Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)

Figure 48 South America Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)

Figure 49 South America Immuno-Oncology Assays Market Share, By Country, 2024 & 2033 (%)

Figure 50 Europe Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 51 Europe Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)

Figure 52 Europe Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)

Figure 53 Europe Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)

Figure 54 Europe Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)

Figure 55 Europe Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)

Figure 56 Europe Immuno-Oncology Assays Market Share, By Country, 2024 & 2033 (%)

Figure 57 Asia-Pacific Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 58 Asia-Pacific Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)

Figure 59 Asia-Pacific Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)

Figure 60 Asia-Pacific Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)

Figure 61 Asia-Pacific Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)

Figure 62 Asia-Pacific Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)

Figure 63 Asia-Pacific Immuno-Oncology Assays Market Share, By Country, 2024 & 2033 (%)

Figure 64 Middle East and Africa Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)

Figure 65 Middle East and Africa Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)

Figure 66 Middle East and Africa Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)

Figure 67 Middle East and Africa Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)

Figure 68 Middle East and Africa Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)

Figure 69 Middle East and Africa Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)

Figure 70 Merck KGaA: Financials

Figure 71 Thermo Fisher Scientific Inc.: Financials

Figure 72 Lunaphore Technologies SA.: Financials

Figure 73 Eve Technologies: Financials

Figure 74 Vivia Biotech S.L: Financials

Figure 75 Illumina, Inc.: Financials

Figure 76 Charles River Laboratories: Financials

Figure 77 Bio-Techne: Financials

Figure 78 Creative Biolabs: Financials

Figure 79 Miltenyi Biotec: Financials

Figure 80 Adipogen Life Sciences: Financials

글로벌 면역항암 진단 키트 시장 – 2023-2030

Global Immuno Oncology Assays Market - 2023-2030